SGLT2s, GLP-1s reduce risk for COPD exacerbations
Sodium-glucose cotransporter 2, or SGLT2, inhibitors and glucagon-like peptide-1 receptor agonists lowered the risk for COPD exacerbation in adults with the disease and type 2 diabetes, researchers reported.Specifically, the treatments’ risk reductions for moderate or severe exacerbations ranged from 14% to 29% vs. dipeptidyl peptidase 4 (DPP-4) inhibitors.